Table 4.
Summary of changes in all survey responses by treatment and time
| Placebo | Ambrisentan | ||||||
|---|---|---|---|---|---|---|---|
| Measure | Change period | Change (95% CI) | Change P -value | Overall P -value | Change (95% CI) | Change P -value | Overall P -value |
| S-HAQ | 1 W - Base | −0.13 (−0.33,0.08) | 0.22 | 0.14 | −0.12 (−0.23,-0.00) | 0.048 | 0.005 |
| 12 W - Base | −0.20 (−0.40,0.00) | 0.051 | −0.20 (−0.32,-0.08) | 0.001 | |||
| 12 W - 1 W | −0.08 (−0.28,0.13) | 0.45 | −0.09 (−0.21,0.03) | 0.15 | |||
| RCS | 1 W - Base | −0.20 (−1.74,1.34) | 0.79 | 0.95 | 0.20 (−0.69,1.09) | 0.65 | 0.001 |
| 12 W - Base | −0.20 (−1.74,1.34) | 0.79 | −1.46 (−2.37,-0.55) | 0.002 | |||
| 12 W - 1 W | −0.00 (−1.54,1.54) | 0.99 | −1.66 (−2.57,-0.75) | <0.001 | |||
| P-VAS | 1 W - Base | 0.20 (−0.95,1.35) | 0.73 | 0.19 | −0.47 (−1.13,0.20) | 0.16 | 0.14 |
| 12 W - Base | −0.80 (−1.95,0.35) | 0.17 | −0.66 (−1.35,0.02) | 0.056 | |||
| 12 W - 1 W | −1.00 (−2.15,0.15) | 0.087 | −0.20 (−0.88,0.49) | 0.56 | |||
P-values are from repeated measure analysis of variance models. Base = baseline; W = week; CI, confidence interval; P-VAS, Visual Analog Scale for Pain; RCS, Raynaud’s Condition Score; S-HAQ, Scleroderma Health Assessment Questionnaire.